Xbrane ‘shifts focus’ to biosimilar portfolio

Xbrane Biopharma has announced that it is shifting its full strategic focus to its biosimilars pipeline in the wake of striking a global co-development deal with Stada for its Xlucane (ranibizumab) rival to Lucentis. The strategic shift means that the Swedish firm will abandon, at least for the time being, development efforts on generic long-acting injectables beyond its existing Spherotide (triptorelin) product.

Xbrane Biopharma has announced that it is shifting its full strategic focus to its biosimilars pipeline in the wake of striking a global co-development deal with Stada for its Xlucane (ranibizumab) rival to Lucentis. The strategic shift means that the Swedish firm will abandon, at least for the time being, development efforts on generic long-acting injectables beyond its existing Spherotide (triptorelin) product.

“As Xbrane’s leading biosimilar Xlucane moves into the pivotal clinical trial,” the firm observed, “Xbrane is accelerating development of Xcimzane...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin